Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Replagal Articles

Shire to acquire FerroKin BioSciences; drops Replagal BLA

16 March 2012

EMA approves Shire Vpriv plant in USA

23 February 2012

Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv

1 September 2011

FDA advisory panel backs approval of Shire’s Firazyr for HAE; Replagal site cleared by EMA

27 June 2011

Shire presents new data for Replagal and VPRIV; gets PUDFA date for Firazyr

22 March 2011

EMEA recommends Replagal as alternative Fabry treatment due to Fabrazyme shortage; FDA approves Shire’s Daytrana for adolescents

7 July 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS